The elucidation of the role of RAC3 in the immune microenvironment and chemoresistance mechanisms opens avenues for the development of personalized medicine approaches, which may ultimately enhance the efficacy of therapeutic strategies and improve clinical outcomes for patients with high-risk BLCA. The gene discussed is RAC3; the disease is bladder transitional cell carcinoma.